Sign in
CompletedPhase 3

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Key facts

Who runs it
Ionis Pharmaceuticals, Inc.
Where
Baltimore, Beverly Hills, Birmingham, Boca Raton, Canton, Charleston, Columbus, Council Bluffs, Edmond, Evanston, Flint, Greenacres City, Greensboro, Gurnee, Homestead, Houston, Huntington Beach, Huntsville, Jackson, Kansas City, La Jolla, Lake Worth, Lansdale, Las Vegas, Lincoln, Little River, Louisville, Manassas, McKinney, Mesquite, Miami, Munster, Nashville, New Port Richey, Northridge, Oakland Park, Ocala, Park Ridge, Plantation, Port Orange, Rapid City, Richmond, Rock Hill, Round Rock, Sacramento, Saint Augustine, Santa Clarita, Stow, Tampa, Tarzana, Torrance, Tucker, Tullahoma, Valencia, and West Des Moines, United StatesSee the 67 sitesAlso in 14 other countries, 105 sites
Status
Completed
Phase
Phase 3
People taking part
1,478 people enrolled
Started
21 Nov 2022
Ended
9 Jun 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Olezarsen
  • Placebo
Record updated
10 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Participants must fall into 1 of the following groups (a or b):; Hypertriglyceridemia with fasting TG ≥200 mg/dL (2.26 millimoles per liter [mmol/L]) and <500 mg/dL (5.65 mmol/L) with either
  • Clinical diagnosis of atherosclerotic cardiovascular disease (ASCVD) or
  • At increased risk for ASCVD; Severe hypertriglyceridemia with fasting TG ≥500 mg/dL (5.65 mmol/L)
  • Participants should be on standard of care (SOC) lipid-lowering medications per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study

Who cannot take part

  • Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening
  • Total bilirubin > 1.5 upper limit of normal unless due to Gilbert's syndrome
  • Estimated GFR < 30 mL/min/1.73 m\^2; NOTE: Other Inclusion/Exclusion criteria may apply
  • Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal

Where in United States

Also in 14 other countries, 105 sites

  • Maryland Cardiovascular SpecialistsBaltimore, United States
  • Cardiovascular Research Foundation of Southern CaliforniaBeverly Hills, United States
  • Westside Medical Associates of Los AngelesBeverly Hills, United States
  • Alabama Clinical Therapeutics, LLC AlabasterBirmingham, United States
  • Excel Clinical Medical TrialsBoca Raton, United States
  • Aultman Hospital Cardiology Clinical TrialsCanton, United States
  • Charleston Area Medical Center (CAMC) Clinical Trials CenterCharleston, United States
  • Medical University of South Carolina (MUSC)Charleston, United States
  • Centricity ResearchColumbus, United States
  • McConnell Heart Health CenterColumbus, United States
  • West Broadway ClinicCouncil Bluffs, United States
  • Central Oklahoma Early Detection CenterEdmond, United States
  • Evanston Premier Healthcare Research LLCEvanston, United States
  • Aa Mrc LlcFlint, United States
  • Finlay Medical Research - West PalmGreenacres City, United States
  • Moses H Cone Memorial HospitalGreensboro, United States
  • Clinical Investigation Specialists, Inc.Gurnee, United States
  • Global Research AssociatesHomestead, United States
  • Baylor College of MedicineHouston, United States
  • Juno Research, LLCHouston, United States
  • Diabetes/Lipid Management & Research CenterHuntington Beach, United States
  • Heart Center Research PCHuntsville, United States
  • The Jackson ClinicJackson, United States
  • University of Kansas Medical Center (KUMC)Kansas City, United States
  • University of California San Diego (UCSD)La Jolla, United States
  • 3Sync ResearchLake Worth, United States
  • Green and Seidner Family Practice AssociatesLansdale, United States
  • Clinical Research of South NevadaLas Vegas, United States
  • Palm Research Center IncLas Vegas, United States
  • Clinical Trials ResearchLincoln, United States
  • Main Street Physicians Care WaterwayLittle River, United States
  • Louisville Metabolic and Atherosclerosis Research CenterLouisville, United States
  • Norton Cardiovascular AssociatesLouisville, United States
  • Carient Heart & VascularManassas, United States
  • Manassas Clinical Research CenterManassas, United States
  • Texas Institute of CardiologyMcKinney, United States
  • Southern Endocrinology AssociatesMesquite, United States
  • Advanced Medical Research Institute (AMRI)Miami, United States
  • De La Cruz Research Center, LLMiami, United States
  • Finlay Medical ResearchMiami, United States
  • Cardiovascular Research of Northwest Indiana, LLCMunster, United States
  • Affinity Health Corp.Nashville, United States
  • Suncoast Clinical Research, Inc. - Palm HarborNew Port Richey, United States
  • Suncoast Clinical Research, Inc._New Port RicheyNew Port Richey, United States
  • Amicis ResearchNorthridge, United States
  • Valley Clinical Trials, Inc.Northridge, United States
  • Proactive Clinical ResearchOakland Park, United States
  • Ocala Cardiovascular ResearchOcala, United States
  • Affinity HealthPark Ridge, United States
  • Comprehensive Medical & Research CenterPlantation, United States
  • Progressive Medical ResearchPort Orange, United States
  • Health ConceptsRapid City, United States
  • Monument Health Clinical ResearchRapid City, United States
  • Reid Hospital and Health Care ServicesRichmond, United States
  • Onsite Clinical Solutions, LLCRock Hill, United States
  • FMC ScienceRound Rock, United States
  • Northern California ResearchSacramento, United States
  • St. Johns Center for Clinical ResearchSaint Augustine, United States
  • Amicis Research CenterSanta Clarita, United States
  • Summit Research Group, LLCStow, United States
  • JSV Clinical Research Study IncTampa, United States
  • Metabolic Institute of AmericaTarzana, United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, United States
  • Atlanta Heart SpecialistsTucker, United States
  • Tennessee Center for Clinical TrialsTullahoma, United States
  • Amicis Research CenterValencia, United States
  • Mercy One Iowa Heart CenterWest Des Moines, United States

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.

The 2 groups in the trial

  • OlezarsenTreatment being tested

    Participants will be randomized to receive multiple doses of olezarsen, once every 4 weeks by subcutaneous (SC) injection up to Week 49.

  • PlaceboPlacebo, for comparison

    Participants will be randomized to receive olezarsen-matching placebo, once every 4 weeks by SC injection up to Week 49.

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia
Publications
Record updated
10 February 2026